Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
US11390624B2 · kind B2 · utility
4Cited by
41References
42Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 28, 2020 |
| Grant date | Jul 19, 2022 |
| Priority date | — |
| Expiry date | Apr 26, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.